TrialJAMA oncology2017
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
Patrick G Gavin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
65 papers cite itlatest 60 shown
this papertrialcites it